TOBRAMYCIN SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C18H37N5O9.5H2O4S
Molecular Weight	1425.421
Optical Activity	UNSPECIFIED
Defined Stereocenters	28 / 28
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@H]1O)O[C@H](CN)[C@@H](O)C[C@H]3N.[H][C@]6(O[C@@H]4[C@@H](N)C[C@@H](N)[C@H](O[C@@]5([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]5O)[C@H]4O)O[C@H](CN)[C@@H](O)C[C@H]6N

InChI

InChIKey=NZKFUBQRAWPZJP-BXKLGIMVSA-N

InChI=1S/2C18H37N5O9.5H2O4S/c2*19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;5*1-5(2,3)4/h2*5-18,24-28H,1-4,19-23H2;5*(H2,1,2,3,4)/t2*5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;;;;;/m00...../s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	14 / 14
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf
Curator's Comment: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
30S ribosomal protein S12 19 Target ID: CHEMBL1641336 Sources: http://www.drugbank.ca/drugs/DB00684#targets	Inhibitor 8297		9.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
External infections of the eye 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50541slr017_tobrex_lbl.pdf	Curative		Approved 8429	TOBREX Approved Use external infections of the eye Launch Date 3.45427214E11
Cystic fibrosis 120 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf	Primary		Approved 8429	KITABIS PAK Approved Use cystic fibrosis Launch Date 1.39216316E12

C_max

Value	Dose	Co-administered	Analyte	Population
3.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
814 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12 mg/kg 1 times / day multiple, intravenous (mean) Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	unhealthy, 2 months - 27 years Health Status: unhealthy Condition: cystic fibrosis Age Group: 2 months - 27 years Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	Sources: https://pubmed.ncbi.nlm.nih.gov/6440126
300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	Other AEs: Forced expiratory volume decreased, Rales... Other AEs: Forced expiratory volume decreased (31%) Rales (19%) Red blood cell sedimentation rate increased (8%) Dysphonia (6%) Wheezing (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	Other AEs: Hypersensitivity, Eyelids itchy sensation of... Other AEs: Hypersensitivity Eyelids itchy sensation of Swelling Redness of eyelid conjunctiva Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
1.5 mg/kg 3 times / day multiple, intramuscular Dose: 1.5 mg/kg, 3 times / day Route: intramuscular Route: multiple Dose: 1.5 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/820195	unhealthy, adult n = 28 Health Status: unhealthy Condition: gram-negative bacilli infection Age Group: adult Population Size: 28 Sources: https://pubmed.ncbi.nlm.nih.gov/820195	Sources: https://pubmed.ncbi.nlm.nih.gov/820195
2 mg/kg single, intraperitoneal Dose: 2 mg/kg Route: intraperitoneal Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	unhealthy, adult n = 5 Health Status: unhealthy Condition: end stage renal disease Age Group: adult Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	Sources: https://pubmed.ncbi.nlm.nih.gov/3950451

AEs

AE	Significance	Dose	Population
Rales	19%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Forced expiratory volume decreased	31%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Wheezing	5%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Dysphonia	6%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Red blood cell sedimentation rate increased	8%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Eyelids itchy sensation of		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Hypersensitivity		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Redness of eyelid conjunctiva		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Swelling		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461 OAT1 599 OAT3 642 OAT2 145 OATP1B1 788 OATP2B1 123 OCT1 512 OCT2 647	P-gp 1537

Drug as perpetrator

Target	Modality	Activity
OATP1B1 803	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT1 543	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT2 648	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OAT2 147	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	no
OATP2B1 126	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0022354921000708 Page: 1612.0	no
OAT1 603	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes
OAT3 644	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.sciencedirect.com/science/article/pii/S0024320501013753 Page: 2908.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28864	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28864
ChemicalBook	CB7154445	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7154445
MolPort	MolPort-003-665-548	https://www.molport.com/shop/molecule-link/MolPort-003-665-548
Selleck Chemicals	Tobramycin(free-base)	http://www.selleckchem.com/products/Tobramycin(free-base).html
ZINC	ZINC000008214692	http://zinc15.docking.org/substances/ZINC000008214692
eMolecules	36516853	https://www.emolecules.com/cgi-bin/more?vid=36516853
eMolecules	3716283	https://www.emolecules.com/cgi-bin/more?vid=3716283

PubMed

Title	Date	PubMed
New and emerging therapies for pulmonary complications of cystic fibrosis.	2001	11558827
The effect of apramycin on colonization of pathogenic Escherichia coli in the intestinal tract of chicks.	2001 Apr	11361100
Fungal keratitis in a daily disposable soft contact lens wearer.	2001 Apr	11352448
The role of nebulized antibiotics in treating serious respiratory infections.	2001 Aug	11589477
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.	2001 Aug	11558860
Mycobacterium keratitis following hyperopic laser in situ keratomileusis.	2001 Aug	11548144
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.	2001 Aug	11545486
In vitro elution of tobramycin from bioabsorbable polycaprolactone beads.	2001 Aug	11514769
Serratia Marcescens corneal ulcer as a complication of orthokeratology.	2001 Aug	11476690
Selective decontamination of the digestive tract in severely burned pediatric patients.	2001 Aug	11451595
Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.	2001 Jan-Feb	11478352
[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].	2001 Jul	11560054
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.	2001 Jul	11471880
Recent advances in cystic fibrosis.	2001 Jul	11420207
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis).	2001 Jun	11572653
Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement.	2001 Jun	11480597
Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999.	2001 Jun	11440331
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.	2001 Jun	11397621
Population kinetics of tobramycin in neonates.	2001 Jun	11360026
Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study.	2001 Jun 1	11380220
In vitro selection of RNA against kanamycin B.	2001 Jun 30	11459219
Statement on the application of the ToBI test for batch potency testing of tetanus vaccines for human use.	2001 Mar-Apr	11379537
[Cloning of the sugar related biosynthesis gene cluster from Streptomyces tenebrarius H6].	2001 May	11517612
Natural antibiotic susceptibility of recently established coryneform bacteria.	2001 May	11453591
Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution.	2001 May	11394943
Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations.	2001 May	11377168
Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology.	2001 May-Jun	11419030
Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs.	2001 May-Jun	11395191
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.	2001 Nov 1	11589975
Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture.	2001 Oct	11592337
Bacillus cereus keratitis associated with contact lens wear.	2001 Oct	11581057
Efficacy and safety of aerosolized tobramycin in cystic fibrosis.	2001 Oct	11568993
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.	2001 Oct	11568989
Aminoglycoside binding to human and bacterial A-Site rRNA decoding region constructs.	2001 Oct	11557348
High-rising terminals and fall-rise tunes in Australian English.	2001 Oct-Dec	11641630
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.	2001 Sep	11678929
Isolation and culture of airway epithelial cells from chronically infected human lungs.	2001 Sep	11669281
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].	2001 Sep	11642015
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin.	2001 Sep	11587466
Recovery from vestibular ototoxicity.	2001 Sep	11568676
Defining a pulmonary exacerbation in cystic fibrosis.	2001 Sep	11562614
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.	2001 Sep	11562127
Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial.	2001 Sep	11555764
Microbiological and immunologic considerations with aerosolized drug delivery.	2001 Sep	11555566
Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.	2001 Sep	11555565
Administration of aerosolized antibiotics in cystic fibrosis patients.	2001 Sep	11555564
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.	2001 Sep	11549103
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.	2001 Sep	11533004
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.	2001 Sep 22	11583754
Aerosols and anti-infectious agents.	2001 Spring	11495486

Patents

Sample Use Guides

In Vivo Use Guide

KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.

Route of Administration: Respiratory

In Vitro Use Guide

High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:20:30 UTC 2023` Edited by `admin` on `Fri Dec 15 16:20:30 UTC 2023`
Record UNII	HJT0RXD7JK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOBRAMYCIN SULFATE

Common Name

English

TOBRAMYCIN SULFATE (2:5)

Common Name

English

NEBCIN

Brand Name

English

GERNEBCIN

Common Name

English

TOBRAMYCIN SULFATE [USP IMPURITY]

Common Name

English

STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1-6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBOHEXOPYRANOSYL-(1-4))-2-DEOXY-, D-, SULPHATE (SALT)

Common Name

English

TOBRADISTIN

Common Name

English

NEBICINA

Common Name

English

TOBRAMYCIN SULFATE [MI]

Common Name

English

TOBRAMYCIN SULPHATE

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL-(1.FWDARW.6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBO-HEXOPYRANOSYL- (1.FWDARW.4))-2-DEOXY-, SULPHATE (2:5) (SALT)

Common Name

English

Tobramycin sulfate [WHO-DD]

Common Name

English

TOBRAMYCIN SULFATE [ORANGE BOOK]

Common Name

English

TOBRA

Common Name

English

OBRACIN

Common Name

English

TOBRAMYCIN SULFATE [USP MONOGRAPH]

Common Name

English

TOBRAMYCIN SULFATE [MART.]

Common Name

English

STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1-6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBOHEXOPYRANOSYL-(1-4))-2-DEOXY-, D-, SULFATE (SALT)

Common Name

English

TOBRAMYCIN SULFATE [VANDF]

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL-(1.FWDARW.6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBO-HEXOPYRANOSYL- (1.FWDARW.4))-2-DEOXY-, SULFATE (2:5) (SALT)

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

536416